| Catalog No. |
Size |
Price |
Figures |
|---|
| Full Name | |
| Abbreviated Name-1 | rHuEPO-α, Erythropoietin alpha, Erythropoietin-a |
|---|
| Abbreviated Name-2 | EPO-alpha, EPO-α, EPO-a, EPOa |
|---|
| Description | GenScript Erythropoietin (EPO)-α, human is a member of the hematopoietic growth factor family. It is one of the few hematopoietic growth factors that behave like hormones. The principal function of erythropoietin is to couple oxygen delivery by circulating red cells to long-term tissue oxygen needs. Produced primarily in the kidneys and to a small extent in the liver in adults, erythropoietin interacts in the bone marrow with specific receptors on the surface of erythroid progenitor cells to initiate their entry into cell cycle if dormant on to maintain their viability while differentiating if they are already in the active part of the cell cycle. Erythropoietin achieves its effects by causing homodimerization of its receptor with the resultant autophosphorylation of the tyrosine kinase JAK2 and phosphorylation of the receptor itself, as well as various substrate proteins leading to the upregulation of a number of signaling pathways and the activation of gene transcription.
Recombinant human erythropoietin-α is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. It is a single, polypeptide chain containing 165 amino acids. The predicted molecular mass is 21,000 Da and the apparent glycosylated molecular mass is 30,400 Da. |
|---|
| Source | CHO cells |
|---|
| M.W. | 30,400 Da |
|---|
| Isoelectric Point | The main zone between 3.3 and 4.3 analysis by IEF |
|---|
| Purity | Greater than 98.0% as determined by the following methods:
(a) SEC-HPLC analysis
(b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis |
|---|
| Endotoxin Level | Less than 0.02 ng/µg (0.02 IEU/µg) determined by LAL test |
|---|
| Specific Activity | The specific activity was 1.2×105 IU/mg. |
|---|
| Storage | Lyophilized rHuEPO-alpha although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution rHuEPO-alpha should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. |
|---|
| Formulation | Each mg of lyophlilzed powder contains 5.8 mg sodium citrate, 5.8 mg sodium chloride and 0.06 mg citric acid. |
|---|
| Reconstitution | It is recommended that the lyophilized rHuEPO-alpha be reconstituted in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
|---|
| Sequence analysis | The sequence of the first fifteen N-terminal amino acids has been determined and was found to be Ala-Pro-Arg-Leu-Ile-Cys-Asp-Ser-Arg-Val-Leu-Glu-Arg-Tyr. |
|---|
